AUTH/3832/10/23 - Complainant v AstraZeneca

Allegations about a video for Forxiga on the AstraZeneca medical platform website

  • Case number
    AUTH/3832/10/23
  • Complaint received
    06 October 2023
  • Completed
    03 December 2024
  • Appeal hearing
    No appeal
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Additional sanctions

Case Summary

This complaint was in relation to a video about chronic kidney disease hosted on AstraZeneca’s website. The complainant alleged that mention of SGLT2 inhibitors was indirect promotion of Forxiga (dapagliflozin). AstraZeneca’s position was that the video was educational and non-promotional, given that it presented a balanced view of the treatment options, without any prominence being given to an AstraZeneca product.

The outcome under the 2021 Code was:

No Breach of Clause 2

Requirement not to bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards at all times

No Breach of Clause 12.1

Requirement to include prescribing information

No Breach of Clause 12.6

Requirement for promotional material on the internet to include a prominent statement as to where prescribing information can be found

No Breach of Clause 12.9

Requirement to include the prominent adverse event reporting statement

No Breach of Clause 15.6

Requirement that promotional material and activities must not be disguised

This summary is not intended to be read in isolation.
For full details, please see the full case report below.